Results 101 to 110 of about 12,401 (156)

Comparison of efficacy and safety of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide fumarate treatment in patients with high viral load of hepatitis B virus. [PDF]

Medicine (Baltimore)
Zhang C, Chen X, Hong Z, Qi Y, Wang X, Dai Y, Qiu Y.   +6 more
europepmc   +1 more source

Efficacy and Safety of Entecavir, Tenofovir Disoproxil Fumarate, and Tenofovir Alafenamide Fumarate in Treating Acute-on-Chronic Liver Failure with Hepatitis B Virus: A Network Meta-analysis. [PDF]

Infect Dis Ther
Liu J, Bi Y, Ma X, Xin Y.
europepmc   +1 more source

Adherence thresholds for emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis against HIV acquisition in cisgender women: A randomized directly observed dosing study. [PDF]

PLoS Med
Mugwanya KK, Saina M, Mugo NR, MaWhinney S, Morrow M, Schaafsma TT, Donnell D, Glidden DV, Ngure K, Brown CE, Rechkina EA, Chohan BH, Wu L, Hill E, Koome E, Akelo N, Mbaire S, Morrison SA, Kibatha M, Njeru I, Muriithi M, Coppinger C, Bushman L, Baeten JM, Anderson PL, Women Benchmark Study Team.   +25 more
europepmc   +1 more source

Weight gain on tenofovir alafenamide fumarate-based therapy compared to tenofovir disoproxil fumarate- and abacavir-based therapy in children and young people living with HIV in Europe. [PDF]

HIV Med
European Pregnancy and Paediatric Infections Cohort Collaboration (EPPICC) Study Group.
europepmc   +1 more source

Long-term metabolic and safety profiles of tenofovir alafenamide and tenofovir disoproxil fumarate in ART-naive people living with HIV: a multicenter retrospective study using a mixed-effects model. [PDF]

BMC Pharmacol Toxicol
Karabay O, Vatan A, Ucar A, Yilmaz I, Balta NC, Kanturk A, Dumlu R, Cag Y, Caskurlu H, Şik MT, Otman ZA, Balci U, Senbayrak S, Akhan S, Deniz MT, Yekenkurul D, Ince N, Tunca B, Cakirca TD, Bastug A, Erkorkmaz U, Guclu E.   +21 more
europepmc   +1 more source

Comparative effectiveness and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in patients with HBV-associated decompensated cirrhosis: insights from a retrospective analysis. [PDF]

BMC Infect Dis
Chen L, Zhang HF, Cai YJ, Zhang L, Cai C, Lu MQ, Zhu YY.   +6 more
europepmc   +1 more source

Sustained HIV Suppression With Co-formulated Tenofovir Disoproxil Fumarate/Lamivudine/Dolutegravir in a Person With Transmitted Dolutegravir Resistance and Pretreatment Resistance to Lamivudine: a Case Report From HPTN 083. [PDF]

Open Forum Infect Dis
Moore HP, Fogel JM, Marzinke MA, Halvas EK, Parikh UM, Mellors JW, Penrose KJ, Seisa M, Petropoulos C, Price AL, Moser A, Wang Z, McCauley M, Valencia-Huamaní J, Rinehart AR, Rooney JF, Soto-Torres L, Grinsztejn B, Landovitz RJ, Eshleman SH.   +19 more
europepmc   +1 more source

Doravirine/lamivudine/tenofovir disoproxil fumarate (DOR/3TC/ TDF) treatment in people living with HIV: A single-center real-world experience from Belgrade, Serbia. [PDF]

Germs
Markovic M, Ranin J, Despotovic A, Rajkovic I, Ranin J, Tanasijevic M, Mitrovic N, Nikolic N, Milosevic I, Gmizic I.   +9 more
europepmc   +1 more source

Switching to besifovir in patients with chronic hepatitis B receiving tenofovir disoproxil fumarate: A randomized trial. [PDF]

Clin Mol Hepatol
Yim HJ, Seo YS, Kim JH, Kim W, Jung YK, Jang JY, Lee SH, Kim YS, Kim CW, Kim HS, Shim JJ, Cho EY, Kim IH, Lee BS, Lee JH, Kim BS, Jang JW, Lee HW, Kwon JH, Kim MY, Song DS, Park JG, Lee YS, Yoon EL, Lee HA, Kang SH, Yang JM.   +26 more
europepmc   +1 more source

Efficacy and safety of doravirine/lamivudine/tenofovir disoproxil fumarate in HIV treatment: a real-world single-center study in China. [PDF]

Front Med (Lausanne)
Li A, Liu L, Zhang H, Wang X, Li Z, Liu A, Dai L, Zhang J, Gao Y, Ye J, Li J, Sun L.   +11 more
europepmc   +1 more source